Powering Global Pharma Innovation: The Rise of Indian CROs
India as the World’s Pharmacy and Global Generic Medicines Leader India supplies more than 20% of the world’s generic medicines, reaching over 200 countries. It provides 40% of generic drugs used in the U.S. and 80% of antiretrovirals globally, reinforcing its pivotal role in affordable global healthcare. While the generic manufacturing engine remains strong, India’s […]
Peptides: A Scientific Revolution in Modern Medicine
Learn about GLP-1 peptides and their revolutionary impact on modern medicine, and how Syngene is enabling this advancement through its state-of-the-art peptide synthesis facility.
The Syngene Advantage: Accelerating Progress Through Integrated Technology Transfer
At Syngene, technology transfer is a seamless, cross-site collaboration, accelerating your journey from concept to commercialization. This video showcases the synergy between our Bangalore (BSEZ) and Mangalore (MSEZ) campuses, driven by robust systems and deep expertise. Our facilities are built for uncompromising quality, proudly GMP certified, 21 CFR compliant, and USFDA approved, ensuring global standards […]
Solving Prep-HPLC Challenges in Early Drug Discovery: Efficient Purification of Unstable Prodrugs via C18 SPE
In the fast-paced world of drug discovery, every day counts—and so does every drop of solvent. Yet for chemists working with polar, unstable prodrugs and new chemical entities (NCEs), one critical step has remained frustratingly slow, expensive, and inefficient: purification.
From Fragile to Agile: Strategic imperatives for strengthening biopharma supply chains
In today’s rapidly evolving world, a resilient supply chain is no longer optional for the biopharma industry; it’s a strategic necessity.
Chiral Inversion Analysis for a Clinical-Stage Biopharmaceutical Company
Learn how Syngene enabled chiral inversion analysis through integrated in vitro and in vivo studies, delivering high-quality data that advanced drug development for a targeted protein degradation program.
Preparation and in-vitro ADME assays screening for rac-Rotigotine prodrugs towards alleviating PD/restless leg syndrome
Learn how Syngene customized ADME assays to identify rac-Rotigotine prodrugs with enhanced bioavailability, which could be used for treating Parkinson’s disease and restless leg syndrome.
Overcoming ADME Challenges in PROTAC Development: Key Insights from Syngene Experts
Targeted protein degraders like PROTACs offer novel therapeutic potential but face ADME hurdles—poor solubility, permeability, and weak IVIVC. Experts Prasoon Chaturvedi (C4 Therapeutics), Vishwottam Kandikere, and Amol Raje (Syngene) discussed solutions.
Bridging the Unbridgeable: The Promise of PROTACs in Drug Discovery
Imagine a world where diseases once deemed “undruggable” are met with targeted, precise therapies. This vision is rapidly becoming a reality, thanks to the revolutionary technology of PROTACs (proteolysis-targeting chimeras).
Elevating Patient Safety: Syngene’s Leadership in Nitrosamine Testing and Comprehensive Analytical Development Services
The pharmaceutical industry has been forced to reckon with the increasing discovery of nitrosamine impurities in drugs, compounds known for their carcinogenic potential. This became especially pronounced in 2018, when several widely used medications, such as Valsartan and Ranitidine, were recalled due to the presence of nitrosamines.